Evidence map›Paper›PMID 36599113›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.

Shawn L Hervey-Jumper, Yalan Zhang, Joanna J Phillips, Ramin A Morshed, Jacob S Young, Lucie McCoy, Marisa Lafontaine, Tracy Luks, Simon Ammanuel, Sofia Kakaizada and 26 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 2 pooled it
44.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Review
  6. Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Observational
  13. Prognostic value of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 4 institutions in 3 countries.

Shawn L Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Yalan ZhangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Joanna J PhillipsDepartment of Pathology, University of California, San Francisco, San Francisco, CA.
Ramin A MorshedDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Jacob S YoungDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-5499-4325
Lucie McCoyDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-2728-6083
Marisa LafontaineDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-2352-3299
Tracy LuksDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.
Simon AmmanuelDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Sofia KakaizadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Andrew EgladyousDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Andrew GogosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-7089-2417
Javier Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-5910-0757
Anny ShaiDepartment of Pathology, University of California, San Francisco, San Francisco, CA.
Gayathri WarrierDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-0716-8012
Terri RiceDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Jason CraneDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-1145-5639
Margaret WrenschDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
John K WienckeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Mariza DarasDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Jennie W TaylorDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0003-3980-5626
Nicholas ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0001-5162-2406
Jennifer ClarkeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Susan ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Edward ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0003-2480-4700
Manish AghiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Philip TheodosopoulosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Michael McDermottDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Asgeir S JakolaDepartment of Neurological Surgery, St Olavs University Hospital, Trondheim, Norway.ORCID 0000-0002-2860-9331
Vasileios K KavouridisDepartment of Neurological Surgery, St Olavs University Hospital, Trondheim, Norway.
Noah NawabiDepartment of Neurological Surgery, Brigham and Women's Hospital, Boston, MA.
Ole SolheimDepartment of Neurological Surgery, St Olavs University Hospital, Trondheim, Norway.ORCID 0000-0002-5954-4817
Timothy SmithDepartment of Neurological Surgery, Brigham and Women's Hospital, Boston, MA.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-9854-7404
University of California, San Francisco · USBrigham and Women's Hospital · USSt Olav's University Hospital · NONorwegian University of Science and Technology · NO

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Immune epigenetic biomarkers of survival in glioma epidemiologyR01CA207360 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2017 to 2021
$3.8M
Intratumoral functional connectivity with implications on synaptogenesis and aphasia recovery in adult astrocytic WHO II-III gliomaK08NS110919 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERVEY-JUMPER, SHAWN L. · 2019 to 2023
$1.0M
NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS L30 CA199570NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA207360NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA151022NCRR NIH HHS UL1 RR024131NINDS NIH HHS K08 NS110919
6 · The paper itself

Abstract

purposeIn patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because a randomized clinical trial with different levels of EOR is not feasible.

methodsIn a 20-year retrospective cohort of 392 patients with IDH-mutant grade 2 glioma, we analyzed the combined effects of volumetric EOR and molecular and clinical factors on overall survival (OS) and progression-free survival by recursive partitioning analysis. The OS results were validated in two external cohorts (n = 365). Propensity score analysis of the combined cohorts (n = 757) was used to mimic a randomized clinical trial with varying levels of EOR.

resultsRecursive partitioning analysis identified three survival risk groups. Median OS was shortest in two subsets of patients with astrocytoma: those with postoperative tumor volume (TV) > 4.6 mL and those with preoperative TV > 43.1 mL and postoperative TV ≤ 4.6 mL. Intermediate OS was seen in patients with astrocytoma who had chemotherapy with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL in addition to oligodendroglioma patients with either preoperative TV > 43.1 mL and residual TV ≤ 4.6 mL or postoperative residual volume > 4.6 mL. Longest OS was seen in astrocytoma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL who received no chemotherapy and oligodendroglioma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL. EOR ≥ 75% improved survival outcomes, as shown by propensity score analysis.

conclusionAcross both subtypes of LGG, EOR beginning at 75% improves OS while beginning at 80% improves progression-free survival. Nonetheless, maximal resection with preservation of neurological function remains the treatment goal. Our findings have implications for surgical strategies for LGGs, particularly oligodendroglioma.

Indexed as

AstrocytomaBrain NeoplasmsGliomaOligodendrogliomaHumansNeurosurgical ProceduresRetrospective StudiesTreatment Outcome

Identifiers

PMID36599113
PMCPMC10082290
OpenAlexW4313544674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.